




1176-72 Simvaetetln Preserves the Structure of Coronary 
Adventit lal  Vase Vseorum in Experimental 
Hypercholeeterolemla Independent of Lipid Lowering 
Joere Herrmann. Stephanie H. Wilson, Erik L. Ritmen, David R. Holmes, ,Jr., Lilach O. 
Lermen, Amir Lerman, Division of Cardiovascular Diseases, Mayo Clinic Rochester, 
Rochester, Minnesota, Division of Anatomic Pathology, Mayo Clinic Rochester' 
Rochester' Minnesota. 
Background: Experimental hypercholesterolemia (HC) is associated with vase vaserum 
(VV) neovascularization prior to lesion formation. Statina have been repeatedly reported 
to have beneficial vascular effects, independent of lipid lowering. Their effect on VV 
neovasculadzation, however, is completely unknown. 
Methods: Female pigs (25-35 kg) were randomized to either normal diet (N, n=5) or high 
cholesterol diet without (HC, n=5) or with simvastatin supplementation (40-80 mg per 
day) (HC+S, n=4) for 12 weeks. The proximal LAD segment was scanned by 3D- 
microCT and VV density was determined in sedal cross-sections. Coronary artery con- 
tent of vascular endothelial growth factor (VEGF) was assessed by immunoblotting and - 
staining. 
Results: Compared to N (84.~ mg/dl), plasma cholesterol was increased in HC and 
HC+S (619±122 and 565±161 mg/dl, p<0.05). Vessel wall area (3.1±0.2 vs. 1.8±0.1 
mm2) and VV density (4.7=-0.3 vs. 2.7±0.2 n/mm2) were increased in HC compared to N 
(p<0.05). This increase in VV density was preserved in HC+S (3.0±0.2 n/mm2), despite 
similar increase in vessel wall area compared to N (2.5±0.1 mm2, p<0.05). In parallel, 
increase in tissue expression of VEGF in HC was preserved in HC+S. 
Conclusions: Simvastatin attenuates the increase in coronary artery VEGF expression 
and prevents VV neovasculadzation in HC, despite no change in plasma lipide. These 
findings underscore the beneficial effect of statins upon vascular alterations in athero- 
sclerosis, independent of lipid lowering. 
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1176-73 Accelerated Neolntima Formation in a Mouse Injury 
Model of Type 2 Diabetes Mellltus: Hyperglycemia, 
Hyperinsullnemla, and Insulin Resistance Following 
Lipid Feeding In the Apolipoprotein-E-Doficient Mouse 
J William Phillies. Kurt G. Barringhaus, John S. Sanders, Ann C. Czarnik, Zandong Yang, 
Meng Chen, Jerry Nadler, lan J. Sarembock, University of Virginia, Charlottesville, 
Virginia. 
Hyperglycamia(HG) and hypednsulinemia(HI) enhance the atherosclerotic omplications 
of diabetes. Using a mouse injury model, we hypothesized that apolipoprotsin E defi- 
cient(apoE-/-) mica fed a Western diet(WD) would develop HI with HG whereas mice on 
a Fructose diet(FD) would develop HI with euglycemia compared Chow diet(CD)and 
neointimal growth would be accelerated in WD fed mice. 
Methods. Female ApoE-/- mice(n=10/group) were fed WD, FD, or CD for 1 week before 
wire injury of the left common carotid artery and continued for 4 weeks. At sacrifice, fast- 
ing glucose, insulin and lipide were measured. Pancreatic islets for insulin release pro- 
files and carotid artades for histomorphometry were harvested. 
Results. See Table. Baseline glucose was normal in all groups. At sacrifice, glucose and 
insulin were higher in the WD group. Insulin release profiles demonstrated loss of the 1 st 
peak and an attenuated 2nd peak in WD group and blunted 1st and 2nd peaks in FD 
group. Gradation in cholesterol and LDL levels was seen in the 3 groups. Neointima for- 
mation was significantly greater in the WD group. 
Conclusions. ApoE -/- mice fed a WD develop HG, HI and an insulin release profile con- 
sistent with type 2 diabetes. FD fed mice maintain euglycemia but develop insulin resis- 
tance. Neointimal growth at 28 days was significantly more robust in the WD group and 
intermediate in the FD group. These models may provide novel insights and an improved 
understandin~l ofatherosclerosis and the response to vascular injury in type 2 diabetes. 
Diet CHOL mg/dL LDL mg/dL Fasting Fasting Neolntlma ~m 2 
Glucoaemg/dL Insulin ng/ml 
Western 1306±100 1133±100 160~15 0.20~0.1 31000~m2±7000 
Fructose "720-+100 *583+90 "113±30 0.15_+0.05 .1100011m2~_2500 
Chow **454±80 **364-+70 #107±18 #0.10~6.03 **5000p.m2_+1000 
*p<0.08 WD VS. FD; **p<0.05 FD VS.CD ; #p~0.05 WD VS. CD 
1176-74 Increased Activity of Endogenous Endothelin-1 in 
Patients With Type 2 Diabetes Mellitus 
Umberto Camoia, Carmine Cardillo, Melissa B. Bryant, Julio A. Panza, Cardiology 
Branch - NHLBI - NIH, Bethesda, Maryland. 
Background: Endothelial dysfunction in patients with diabetes may contribute to their 
risk of premature atherosclerosis. Endothelin (ET-1), a peptide released by endothelial 
cells, may be involved in this process by activating smooth muscle cell mitogenesis and 
leukocyte adhesion. We sought to assess the activity of endogenous ET-1 in a group of 
patients with non-insulin-dependent diabetes meltitus (NIDDM) by use of antagonists of 
ET-1 receptors. 
Methods: Forearm blood flow (FBF) responses (strain gauge plethysmography) to 
intraarterial infusion of a selective blocker of ET A receptors (BQ-123) and, on a different 
occasion, to ET-1, were measured in 15 NIDDM patients and 12 healthy controls. In addi- 
tion, 5 NIDDM patients received co-infusion of BQ-123 and BQ-788 (a selective blocker 
of ET A receptors). 
Results: In normal subjects, BQ-123 did not significantly modify FBF from baseline 
(P=0.16); in NIDDM patients, in contrast, BQ-123 administration resulted in a significant 
vasodilator esponse (P<0.001). Infusion of exogenous ET-1 resulted in lower vasocon- 
strictor responses in NIDDM patients than in controls (P=0.001), whereas vasoconstrictor 
responses to norapinephdne were similar in the 2 groups (P=0.78). In NIDDM patients, 
the vasodilator esponse to selective ET A blockade was not significantly modified by non- 
selective blockade of ET-1 receptors obtained by co-infusion of BQ-123 and BQ-788. 
Conclusions: 
The activity of endogenous ET-1 is enhanced in resistance vessels of NIDDM patients, 
whereas their sensitivity to exogenous ET-1 is blunted. Due to the atherogenetic proper- 
ties of ET-1, this abnormality may participate in the pathophysiology of the vascular dis- 
ease in diabetic patients. 
1176-95 Cigarette Smoke Creates an Unstable AtheroscleroUc 
Plaque Phenotype by Enhancing Vascular Oxidative 
Stress, Increasing Vascular Endotbellal Growth Factor 
Expression and Producing Collagen Loss In ape E -/- 
Mice 
Takeo Anazawa, Juliana Yano, Xioanino Zhao. Sanjay Kaul, Paul Dimayuga, Kuang-Yuh 
Chyu, Bojan Cercak, Prediman K. Shah, Cedars-Sinai Medical Center, Los Angeles, 
California. 
Background: The mechanism by which smoking increases risk for acute cardiovascular 
events is unclear. By altering vascular oxidative stress, pro-inflammatory gene expres- 
sion, and elaboration of angiogenic ytokines such as VEGF, smoking may enhance col- 
lagen degradation through MMP activation and change plaque composition. The aim of 
this study was to determine the effect of cigarette smoke on plaque phenotype, vascular 
oxidative stress and VEGF expression, in apoE-/* mice. 
Method: After exposing mice to cigarette smoke (1 cigarette/day) for 26 weeks, aortic 
sinus plaque collagen and lipid content was measured. An additional group of mice were 
exposed to cigarette smoke for 8 weeks and their aortic extracts were examined by 
Western blot for redox sensitive c-Jun and Ref-t. VEGF expression was studied by 
immunohistochemistry in aortic sinus plaques and Western blot of aortic extracts. Immu- 
noreactivity is presented as percent positive stained area of plaque. 
Results: 
Long-term Lipid area Collagen area 
No exposure 15.2+1.1%;n=3 55.3+7.5%;n=3 
Cigarette smoke 17.2±7.6%;n=8 35.7+7.3%#; n=3 
Short-term c-Jun* Ref-t* VEGF* % VEGF staint 
No exposure 1.8±0.5 x 104 1.6+0.2 x 104 7.6±0.9 x 104 5.6+3.9% n=6 
Cigarette smoke 3.2_+0.4 x 104# 2.9_+0.7 x 104# 10.2±0.9 x 104# 13.6-+5.0% # n=8 
*Relative densitometric units, n=4 each. tPement stain of aortic sinus plaque. 
#p<0.05 vs. No exposure. 
Conclusion: Long-term exposure to cigarette smoke results in reduced plaque collagen 
content creating a more unstable plaque phenotype in ape E -/- mice. Evidence of 
enhanced redox sensitive gene expression (c*Jun and Ref-t) coupled with enhanced 
VEGF expression during short-term smoke exposure suggests that increased vascular 
oxidative stress and angiogenic ytokines may mediate the effects of cigarette smoke on 
plaque phenotype. 
1176-96 Selective Inducible Nitric Oxide Synthase Inhibitor 
Mercaptoethylguanidlne Attenuates Neointimal 
Formation in Injured Mice Exposed to Cigarette Smoke 
Takeo Anazawa, Hongyan Li, Xioaning Zhao, Juliana Yano, Kuang-Yuh Chyu, Sanjay 
Kaul, Prediman K. Shah, Bojan Cercek, Cedars-Sinai Medical Center, Los Angeles, 
California. 
Background: Cigarette smoking and hypercholesteremia are synergistic risk factors of 
coronary heart disease. We have previously shown that iNOS is associated with an 
increased artedal wall response to injury. We sought to determine the effects of smoking 
and hypercholesteremia on the response to arlerial injury in C57/BI6J mice and hyperc- 
holesterolemic ApoE -/-. The role of iNOS in modulating the response was examined 
using selective iNOS inhibitor mercaptcathylguanidine (MEG). 
Methods: We used a mouse model of vascular injury induced by placing a periadventitial 
collar around the right carotid artery. Eleven C57BI/6J mice were exposed to smoke of 1 
cigarette/day, with (n=7) or without (n=5) MEG treatment. Sixteen ApoE -/- mice were 
exposed to cigarette smoke with (n=12) or without (n=4) MEG treatment. Control C57BI/ 
6J (n=6) and ApoE -/- (n=11) mice were exposed to room air without MEG treatment. 
Expression of iNOS was analyzed by western blot. 
Results: 
Neolntlmal area (mlcrom sq.) 21 days after Injury: 
Group Control Cigarette smoke Cigarette smoke+MEG 
C57BI/6J 9.3 +/- 7.6 23.3 +/- 12.9" 7.3 +/- 5.4t 
ApoE-/- 22.4 +/- 21.3 49.0 +/- 30.2* 66.7 +/- 60.2 
*p<0.05 vs. control; tp<0.05 vs. Cigarette smoke 
iNOS expression in MEG-treated C57BI/6J mice exposed to smoke was less compared 
to mice without MEG treatment. 
Conclusion: Exposure to cigarette smoke increased neointimal thickening after arterial 
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wall injury in C57BIJ6J mice and ApoE-/-mice. Treatment with MEG reduced neointimal 
thickening only in C57BIJ6J mice, suggesting a selective role for iNOS. In addition, ciga- 
rette smoking and hypercholesterolemia may have a synergistic effect on oxidative 
stress response to arterial injury in mice. 
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1177-87 The Protective Effect of the T(-107)C Promoter 
Polymorphiam of the Paraoxonase Gene in Arterial 
Thrombotic Disease 
Barbara Voetsch, Kelly S. Benke, Benito P. Damasceno, Lucia H. Siqueira, Joseph 
Loscalzo, Boston University Medical Center, Boston, Massachusetts, State University of 
Campinas, Campinas, Brazil. 
Background: Approximately one-third of patients with arterial thrombotic disease do not 
have traditional cardiovascular risk factors. Serum paraoxonase (PON) is an HDL-asso- 
ciated esterase that hydrolyzes products of lipid peroxidation and prevents the oxidation 
of LDL. PON levels are significantly reduced in patients with coronary heart disease. 
Recently, two PON promoter polymorphisrns, T(-107)C and G(-624)A, were identified 
that are consistently associated with lower PON expression and activity; however, it is 
not known if these polymorphisms are a risk factor for arterial thrombotic disease. 
Methods: We studied the PON promoter genotypes and vascular risk factors of 115 
patients (63 women, mean age: 35.8 _+ 6.9 years) with a clinically and radiologically 
defined arterial ischemic stroke occurring before the age of 45 years and 117 age- and 
gender-matched controls. To identify the T(-107)C polymorphism, we used non-radioac- 
tive single-strand conformational polymorphism analysis of a 129 bp-sized fragment con- 
taining the polymorphic site. 
For detection of the G(-824)A polymorphism, a 200 bp fragment was amplified using a 
mutagenic primer, resulting in an artificial restriction site for Pvu II when the polymorphic 
G nucleotide was present. 
Results: When analyzing the PON T(-107)C polymorphism, we found that the TT geno- 
type was significantly less frequent among patients than controls (12.2% vs. 22.2%, 
P=0.041). In a logistic regression model adjusting for arterial hypertension, smoking, dia- 
betes mellitus and hyperlipoproteinemia, this association remained significant 
(P=0.0297, OR=0.41,95% CI 0.19 to 0.9). Regarding the PON G(-824)A polymorphism, 
there was no significant difference between groups (P=0.47). 
Conclusion: These findings suggest that the PON -107T allele may have a protective 
effect against arterial thrombotic disease in young adults. Studies including a larger num- 
ber of patients and analyzing the effect of PON on atherothrombosis are necessary to 
understand better the mechanistic role of these observations in the development of arte- 
rial disease in the young. 
1177-88 Variability in Inhibition of Platelet Aggregation With 
Clopidogrel and Correlation With ADP-Induced P- 
Selectin Expression on Platelets 
Michael Anaioi, Pierre Theroux, Marta Ghitescu, Richard Gallo, Many Frojmovic, 
Montreal Heart Institute, Montreal, Quebec, Canada. 
Background: Thienopyridines inhibit platelet activation and aggregation by blocking the 
ADP P2Y12 receptor. We investigated the correlation between platelet aggregation and 
activation in patients treated with clopidogrel. 
Methods: Patients (n=19) with stable angina were assessed before and after 1 week 
treatment with 75 mg of clopidogrel given daily. Blood samples were anticoagulated with 
PPACK-hirudin. Platelet aggregation (TA) in stirred platelet rich plasma (PRP) and micro- 
aggregate formation (PA) in 1:10 diluted PRP at a shear stress of 1000s "1 were studied. 
In addition, flow cytometry was used to measure platelet activation, (P-selectin for secre- 
tion; and PAC-1 for free activated GPIIb/llla) after 10 p.M ADP stimulation. 
Results: Treatment by clopidogrel significantly reduced aggregation for both TA (65-+8 vs. 
45+15%, p<0.0001 ) and PA (84+8 vs. 49_+18 %, p<0.0001 ). Inhibition varied widely, from 
0 to 65% for TA; and from 0 to 70% for PA. Clopidogrel significantly decreased P-selectin 
expression (40±15 vs. 14±8%, p<0.0001) as well as PAC-1 binding (60±30 vs. 23+~?.0, 
p<0.001), By Linear regression analysis the magnitude of inhibition of platelet aggrega- 
tion correlated weakly with PAC-1 levels (R-square=0.17, p=0.08 for both TA and PA), 
but strongly with inhibition of P-selectin expression (R-square=0.28, p<0.02 and R- 
square=0.40, p<0.004, respectively). When inhibition of aggregation attained levels 
greater than 30% for TA and 25% for PA, P-selectin was always expressed by less than 
20% of platelets. 
Conclusion: Inhibition of platelet aggregation by clopidogrel was found to be highly vari- 
able. Inhibition may depend less on reduced free activated GPIIb/llla, where few recep- 
tors may be required to support aggregation, and more on reduced secreted adhesive 
ligands, Determination of P-selectin may be helpful to assess the anti-aggregant efficacy 
of clopidogrel. 
1177-89 The Relationship Between Serotonin 2A Receptor Gene 
Polymorphiems and Serotonin Induced Platelet 
Aggregation 
Masakatsu Shirnizu. Hozuka Akita, Nobuyuki Shiga, Eiji Takai, Chikao Iwai, Yoshitomo 
Miyamoto, Yukie Jyoukei, Shunichi Kumagai, Masayoshi Hashimoto, Mitsuhiro 
Yokoyama, Division of Cardiovascular and Respiratory Medicine, Kobe University 
Graduate School of Medicine, Kobe, Japan, Division of General Medical Science, Kobe 
University Graduate School of Medicine, Kobe, Japan. 
Background: Serotonin (5-HT) induces platelet aggregation (PA) and increases the vas- 
cular tonus through 5-HT2A receptor activation. Recently two common polymorphisms in 
the 6-HT2A receptor gene, T102C in exon 1 and -1438NG in the promoter, was identi- 
fied. We and others showed that these polymorphisms were associated with myocardial 
infarction or psychological disorder, However, these functional significance remains 
unknown. 
Methods: We investigated 5-HT2A receptor gene polymorphisms by PCR-RFLP and PA 
by using a novel laser-light scattering method in 33 young healthy volunteers (mean age 
26.4_+1.5SD). PA was induced by 5-HT 0.3, 1.0~M and ADP 0.1, 0.3HM, and evaluated 
by the peak of small aggregation counts. 
Results: (1)T102C polymorphism: The peak of PA induced by 5-HT in TT genotype was 
significantly higher compared with TC and CC genotype (Table), However, this polymor- 
phism did not influence ADP-induced PA. 5-HT concentration in platelet rich plasma 
(PRP) was not different between 2 groups. 
(2)-1438A/G polymorphism: A allele frequencies were 0.59 (AA: n=9, AG: n=21, GG: 
n=3). 5-HT-induced PA was not different between 2 groups (AA vs. AG+GG: 5-HT 0.31~M; 
30.8+11.4SEMx103 vs. 21.5+6.6SEM×103, NS, 5-HT 1.0~M;128.7+17.6SEM×103 vs. 
90.9~_12.2SEM×103, NS ). In addition, this did not influence ADP-induced PA. 
Conclusion: The T102C polymorphism was associated with 5-HT-induced PA, but the - 
1438A/G was not. This is the first report demonstrating the functional significance of the 
T102C polymorphism. 
T1O2C polymorphlsm, platelet aggregation, end 5-HT concentration in PRP 
TT(n=5) TC+CC(n=22+6) p 
5-HT 0.311M, x103 51.2±15.1 19.2±5.8 <0.05 
5-HT 1 .OHM, ×103 168.0±10.2 89.3±10.6 <0.005 
ADP 0.1~M, xl03 15.5±6.7 15.8¢5.4 NS 
ADP 0.3~M, xl03 161.2±25.9 92.7±14.3 NS 
5-HT in PRP, I~g/ml 0.28±0.01 0.26±0.02 NS 
1177-90 Increased Tissue Plasminogen Activator Antigen Is 
Predictive of Cardiovascular Events in the Veterans 
Affairs HDL Intervention Trial (VA-HIT) 
Geoffrev H. Taller, Sander J. Robins, Dorothea Collins, Izabela Lipinska, Prakash C. 
Deedwania, Hanna C. Rubins, Royal North Shore Hospital, Sydney, Australia. 
Background: Hemostatic factors have been shown to be predictive of future cardiovascu- 
lar disease events (CVD), although this has not been well studied in patients with known 
CVD and low HDL-CholesteroL 
Methods: We prospectively studied 829 subjects who were enrolled in the Veterans 
Affairs HDL Intervention Trial (VA-HIT). Enrolment criteria included known CVD and low 
HDL-cholesteroL Tissue plasminogen activator (TPA) antigen, factor VII antigen and 
fibrinogen were determined at baseline and after 1 year of therapy with placebo or gemfi- 
brozil. There was no effect of gemfibrozil on these measures of hemostasis. Thus, data 
from the gemfibrozil and placebo arms were combined. 
Results: During follow-up (median 5.1 years),140 patients had as a first event nonfatal MI 
or cardiac death. Relative risks (RR) were determined by multivariate Cox models, 
adjusting for age, hypertension, diabetes, smoking, body mass index, compliance and 
treatment. 
Results: Higher tPA antigen levels were associated with increased cardiovascular risk 
(4.7% for each unit tPA increase), whereas fibrinogen and factor VII were not significant 
predictors. 
Conclusion: Reduced fibrinolytic potential, as evidenced by increased tPA antigen levels, 
was a significant predictor of cardiovascular events in patients with known CVD and low 
HDL. Measurement of tPA may provide prognostic value in this subjects. Strategies to 
improve fibrinolytic potential in this population warrant further investigation. 
MI/Cardiac Death 
RR 95% CI p-value 
tPA antigen (ng/ml) 1.047 1.004-1.092 0.03 
Factor VII antigen (%) 1.002 0.990-1.014 0.78 
Fibrinogen (mg/dl) 0.999 0.996-1.002 0.90 
1177-91 Investigation of Thrombocytopenla In Individuals 
Receiving GPIIb-Illa Antagonist Therapy 
Lisa K. Jenninos. Steven Slack, Shila Cholera, Melanie White, Lou Ann Keith, Mary V. 
Jacoski, Sophie Combe, University of Tennessee Health Science Center, Memphis, 
Tennessee. 
Background: The use of GPfib-Illa antagonists for treatment of acute coronary syn- 
dromes continues to rise, as studies consistently demonstrate a significant benefit in 
reducing ischemic endpoints, Thrombocytopenia (TCP) is an infrequent, yet serious 
potential side effect of GPIIb-Illa antagonists. Little is known about the mechanism 
behind its development, therefore it is often impossible to predict which patient is at risk 
at the treatment onset. These patients are also concurrently treated with several drugs 
